Your Drug, My Drug, or Our Drugs: How Aggressive Should We Be With Antihypertensive Therapy?-Reference-Cited by-同舟云学术

Your Drug, My Drug, or Our Drugs: How Aggressive Should We Be With Antihypertensive Therapy?

Published:2005-08 Issue:s8 Volume:7 Page:5-7
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:The Journal of Clinical Hypertension

Author:

Izzo Joseph L.¹

Affiliation:

1. From Erie County Medical Center and the Department of Medicine, Division of Clinical Pharmacology, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1524-6175.2005.04609.x

Reference11 articles.

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 Report

2. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

3. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

4. A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease

5. Second Australian National Blood Pressure Study (ANBP2): Australian Comparative Outcome Trial of ACE inhibitor- and Diuretic-based Treatment of Hypertension in the Elderly:Management Committee on behalf of the High Blood Pressure Research Council of Australia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EXCEED: Exforge®-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics;Therapeutic Advances in Cardiovascular Disease;2009-07-28

2. Inhibiteurs de l’enzyme de conversion et antagonistes calciques : une synergie d’action pour une meilleure prévention des événements cardiovasculaires;Therapies;2009-07